← All trials
NCT05935826
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Jun 30, 2026
- First posted
- Jul 7, 2023
- Last posted
- Jul 30, 2024
- Enrollment
- 55
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Colorado, DenverLead sponsor
- University of ColoradoOfficial
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.